Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman diseaseRazelle Kurzrock, Peter M Voorhees, Corey Casper, et al.
The Lancet. Haematology|December 5, 2016
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 studyRichard R Furman, Herbert A Eradat, Christine G DiRienzo, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Role of Surveillance Imaging in Patients With Peripheral T-Cell LymphomaTiffany Tang, Zhengming Chen, Pannee Praditsuktavorn, et al.
Blood|March 31, 2021
Acalabrutinib in treatment-naive chronic lymphocytic leukemiaJohn C Byrd, Jennifer A Woyach, Richard R Furman, et al.
Blood|February 21, 2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Haematologica|March 30, 2019
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapyAnthony R Mato, William G Wierda, Matthew S Davids, et al.
British Journal of Haematology|April 12, 2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinibJeffrey A Jones, Peter Hillmen, Steven Coutre, et al.
British Journal of Haematology|October 28, 2008
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myelomaTomer Mark, David Jayabalan, Morton Coleman, et al.
Blood|January 2, 2014
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemiaJohn C Byrd, John M Pagel, Farrukh T Awan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSteven E Coutré, Richard R Furman, Ian W Flinn, et al.
Pageof 14